諾誠健華-B(09969.HK)公開發售超購297.75倍 3月23日上市
格隆匯3月20日丨諾誠健華-B(09969.HK)公佈,公司擬發售2.5億股,其中香港公開發售1.25億股,國際發售1.25億股,每股發行價8.95港元。每手1000股,預計3月23日上市。
香港公開發售獲非常大幅超額認購,合共接獲132,798份有效申請,認購合共74.79億股香港發售股份,相當於香港公開發售初步發售股份總數2503.4萬股約298.75倍,由於超額認購多於100倍,故已採取重新分配程序,香港公開發售項下的發售股份最終數目為1.25億股。
根據國際發售初步提呈發售的發售股份已獲非常大幅超額認購併已超額分配3754.8萬股發售股份,國際發售的最終數目為1.25億股。此外,基石投資者已合共認購1.25億股發售股份。
根據國際發售,495萬股發售股份配售予UBSAG香港分行(為聯席全球協調人及聯席賬簿管理人之一)的關連客户UBS Asset Management (Singapore) Limited。就全球發售而言,公司已向國際包銷商授出超額配股權,可由聯席全球協調人內行使,要求公司按發售價發行最多3754.8萬股額外發售股份(相當於根據全球發售初步可供認購的發售股份約15%)。
全球發售收取的所得款項淨額估計約為20.93億港元,約50.0%將用作為奧布替尼在中國及美國同意同時正在進行和計劃進行的臨牀試驗、準備註冊文件及潛在的商業推出(包括銷售和營銷)提供資金;預期約25.0%將用作為我們的兩個臨牀階段候選產品提供資金;預期約15.0%將用作為公司管線中的六種IND準備階段的候選藥物的研發以及新候選藥物的研發及外部引進提供資金;預期約10.0%將用作公司的營運資金及其他一般企業用途。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.